We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byCorey Hunter
Modified about 1 year ago
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle- Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, and Hartmut Döhner Blood Volume 123(21): May 22, 2014 ©2014 by American Society of Hematology
Incidence and distribution of gene mutations, genomic aberrations, and IGHV status for the patients with all markers available (n = 573). Stephan Stilgenbauer et al. Blood 2014;123: ©2014 by American Society of Hematology
Kaplan-Meier estimates. Stephan Stilgenbauer et al. Blood 2014;123: ©2014 by American Society of Hematology
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis by Thet Thet Lin, Boitelo T. Letsolo,
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG) by Peter Paschka,
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,
Lymphoma & Myeloma 2014 October 24, 2014 Obinutuzumab: Analysis of it’s Pivotal Data Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma.
Should Chlorambucil Be Used with Obinutuzumab in Untreated CLL? Answer: YES! Myron S. Czuczman, MD Chief, Lymphoma/Myeloma Section Head, Lymphoma Translational.
The genetic basis of myelodysplasia and its clinical relevance by Mario Cazzola, Matteo G. Della Porta, and Luca Malcovati Blood Volume 122(25):
Investigating a New Methodology for the Detection of Low Frequency 17p Deleted Clones in Chronic Lymphocytic Leukaemia (CLL): Impact on Prognostic Outcome.
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease by Françoise Bernaudin, Gérard Socie, Mathieu Kuentz,
IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.
Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a.
MicroRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia by Daniela Asslaber, Josefina.
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.
1 EBMT Lymphoma Working Party 11th Educational Course Treatment of Malignant Lymphoma: State of the Art and the Role of Stem Cell Transplantation
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations by Susan Price, Pamela A. Shaw, Amy Seitz, Gyan Joshi, Joie.
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.
The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia by Alessandra Ferrajoli, Michael J. Keating,
Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.
Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with.
How I treat HHV8/KSHV-related diseases in posttransplant patients by Giovanni Riva, Mario Luppi, Patrizia Barozzi, Fabio Forghieri, and Leonardo Potenza.
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts by Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria.
Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases by Porcia T. Bradford, Susan S. Devesa, William F. Anderson,
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor.
Making Sense of Novel Prognostics: NOTCH1, SF3B1 Jennifer R Brown, MD PhD Director, CLL Center Dana-Farber Cancer Institute October 24, 2014.
JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura by Donald M. Arnold, Ishac Nazi, Aurelio Santos,
Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification by Paolo Strati, and.
Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,
Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs) by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology by Tomas Radivoyevitch, Lynn Hlatky, Julian Landaw, and Rainer K. Sachs Blood.
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis by Marcello Di Nisio, Anne W. S. Rutjes, Noemi.
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma ASH Review 2012 Stephen Spurgeon
Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes by Marie Scully, Mari Thomas, Mary Underwood,
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study by Andreas Tiede, Robert Klamroth,
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone by Allan Pamba, Naomi D. Richardson,
© 2017 SlidePlayer.com Inc. All rights reserved.